Table 226 Serum vitamin D and colorectal cancer risk. Results of meta-analyses and pooled analyses of prospective studies published after the 2010 SLR. Total Number of cohort Studies Author, Year number Outcome Comparison RR (95%CI) P studies country, area (I2, p of cases Meta-analysis Incidence, 8 2 690 0.66 (0.54-0.81) colorectal cancer North Incidence, colon Highest vs 9 1 822 0.77 (0.56-1.07) Lee, 2011 America, cancer lowest Europe, Asia Incidence, rectal 8 868 0.50 (0.28-0.88) cancer 9 Incidence, (case-control and cohort 2 630 0.85 (0.79-0.91) 55%, <0.01 Gandini, 2011 USA colorectal cancer studies) Table 227 Serum vitamin D and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response analysis Cases/ Author, Year, Missing data Study name, Study size Case Exposure RR (95%CI) Adjustment WCRF Code, Outcome Comparison derived for characteristics Follow-up ascertainment assessment Ptrend factors Country analyses (years) vs 50-75 ≥100 0.40 (0.17-0.92) Weinstein, 2015 PLCO, 476/ Self-report nmol/l Incidence, COL41025 474 Nested controls Case verified by colorectal cancer Q 5 vs Q 1 0.59 (0.36-0.95) USA 5.6 Control, years medical record per 25 nmol/l 0.77 (0.65-0.91)
Table 226 Serum vitamin D and colorectal cancer risk. Results of meta-analyses and pooled analyses of prospective studies published after the 2010 SLR. Author, Year Number of cohort studies Total number of cases Studies country, area Outcome Comparison RR (95%CI) P (I2, p Meta-analysis Lee, 2011 8 2 690 North America, Europe, Asia Incidence, colorectal cancer Highest vs lowest 0.66 (0.54-0.81) 9 1 822 Incidence, colon cancer 0.77 (0.56-1.07) 8 868 Incidence, rectal cancer 0.50 (0.28-0.88) Gandini, 2011 9 (case-control and cohort studies) 2 630 USA Incidence, colorectal cancer 0.85 (0.79-0.91) 55%, <0.01 Table 227 Serum vitamin D and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response Author, Year, WCRF Code, Country Study name, characteristics Cases/ Study size Follow-up (years) Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Missing data derived for analyses Weinstein, 2015 COL41025 USA PLCO, Nested Case Control, 476/ 474 controls 5.6 years Self-report verified by medical record Incidence, colorectal cancer ≥100 vs 50-75 nmol/l 0.40 (0.17-0.92) Q 5 vs Q 1 0.59 (0.36-0.95) per 25 nmol/l 0.77 (0.65-0.91) analysis
CUP_colorectal_SLR_2016_RO.docx